Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Meta Is Building an AI Version of Mark Zuckerberg to Interact With Employees 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Baker Hughes Sells Waygate Technologies to Hexagon for $1.45 Billion 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Jefferies Upgrades Starbucks to Hold as China JV Deal Closes and U.S. Business Shows Signs of Recovery 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
WASHINGTON, April 11, 2016 -- Tomorrow, the Regenerative Medicine Foundation (RMF) will co-host an event with the Bipartisan Policy Center (BPC) on advancing the availability and use of safe and effective regenerative cell therapies in the United States. The April 12th event, Advancing a New Policy Framework for Regenerative Cell Therapy—which begins at 9:30am EST and will be webcast live—will bring together scientific and academic experts, patients, practitioners, and industry to discuss the science behind cell therapy and new policies needed to modernize the current U.S. regulatory approach.
In addition to co-hosting the event, the Regenerative Medicine Foundation is collaborating with BPC to convene and engage a broad societal-based alliance of non-profit patient groups, medical philanthropies, academic centers, industry organizations, and other advocates to support a new regulatory pathway for safe and effective cell therapies in the U.S.
"With the recent introduction of the bipartisan, bicameral REGROW Act, the time has arrived for us to move from laboratories into the clinic," said Bernie Siegel, executive director of the Regenerative Medicine Foundation and founder and chair of the annual World Stem Cell Summit & RegMed Capital Conference. "Cell therapies are different from drugs, and they have the vast potential to alleviate human suffering. We need to support the FDA in accelerating safe and effective cell therapy treatments, and the Regenerative Medicine Foundation is committed to this humanitarian cause."
"We are delighted to be working with the Regenerative Medicine Foundation to advance regenerative cell therapy—which represents one of the most promising areas for the next generation of groundbreaking treatments," said Janet Marchibroda, director of BPC's health innovation initiative. "Through our work together, we are advancing public policy that will accelerate the availability of safe and effective treatments for Americans and improve U.S. competitiveness in the global marketplace."
About the Regenerative Medicine Foundation
The nonprofit Regenerative Medicine Foundation, formerly known as the Genetics Policy Institute, is an influential global network of stakeholders from patient-advocacy, science, and industry that serves as a catalyst and provides leadership to the pro-cures movement. Through RMF's action network, reports, newsletters, the flagship World Stem Cell Summit and RegMed Capital Conference, special projects, speaking engagements, world-renowned advisory boards, educational resources, teaching initiatives, and strategic relationships, RMF serves as the foremost channel of knowledge between leading regenerative medicine experts, patient advocates, and those who make policy for the general public.
CONTACT: Alan Fernandez
650-759-8300
[email protected]
